AGArianna Gabrieli

Arianna Gabrieli

*This is an algorithmically generated author record based on publicly available information.

Arianna Gabrieli has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    XBB.1.5-Adapted COVID-19 Vaccines in Patients with Cancer: Comparative Immunogenicity of mRNA and Protein-Based Platforms

    by Maciej Stanislaw Tarkowski, Davide Dalu, Letizia Oreni, Craig Fenwick, Céline Pellaton, Arianna Gabrieli, Valeria Colombo, Shabab Hussain, Giuseppe Lipari, Lorenzo Ruggieri, et al.

    IntroductionCancer is an underlying medical condition associated with an increased risk of severe COVID-19. Both malignancy and anticancer therapies may impair host immune defenses, thereby increasing susceptibility to severe disease. In Italy, the mRNA-based Comirnaty XBB.1.5 and adjuvanted recombinant spike protein-based Nuvaxovid XBB.1.5 vaccines were recommended for older and immunocompromised individuals to maintain protection against COVID-19. This study compared the immunogenicity of these vaccines in patients with cancer.MethodsTotal immunoglobulin levels against SARS-CoV-2 antigens and IgG neutralizing antibody titers against five viral variants were measured before and after vaccination.ResultsBoth vaccines induced significant increases in IgG antibodies against the SARS-CoV-2 XBB.1.5 variant in patients with cancer, irrespective of recent SARS-CoV-2 exposure before vaccination. However, the response rate and immunogenicity of Comirnaty XBB.1.5 were significantly higher than those of Nuvaxovid XBB.1.5. Multivariable analyses confirmed significantly greater immunogenicity with Comirnaty XBB.1.5 against the XBB.1.5 and BA.2.86 variants. The vaccine-induced fold change in neutralizing antibody titers was not significantly associated with age, corticosteroid therapy, the number of previous COVID-19 vaccine doses, the interval between vaccination and post-vaccination sampling, or recent SARS-CoV-2 exposure.ConclusionsOur findings support previous evidence that mRNA-based COVID-19 vaccines elicit stronger antibody responses and extend this observation to patients with cancer. These results may inform vaccination strategies for immunocompromised populations, in whom maximizing vaccine-induced protection against severe COVID-19 remains a key objective.

  • Open Access

    HIV‐DNA decrease during treatment in primary HIV‐1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial

    by Elena Bruzzesi, Arianna Gabrieli, Davide Bernasconi, Giulia Marchetti, Andrea Calcagno, Diego Ripamonti, Andrea Antinori, Nicola Squillace, Antonella Cingolani, Antonio Muscatello, et al.

    As the introduction of antiretroviral therapy (ART) during primary HIV‐1 infection (PHI) could restrict the establishment of HIV reservoirs, we aimed to assess the effect of three different ART regimens on HIV‐DNA load in people living with HIV (PLWH), who started ART in PHI. Randomized, open‐label, multicentric study, including subjects in PHI (defined as an incomplete HIV‐1 Western blot and detectable plasma HIV‐RNA) in the Italian Network of Acute HIV Infection cohort. Participants were randomly assigned (10:10:8) to a fixed‐dose combination of tenofovir alafenamide fumarate (TAF) 10 mg plus emtricitabine (FTC) 200 mg, darunavir 800 mg, and cobicistat 150 mg once daily (group A), or TAF 25 mg plus FTC 200 mg, dolutegravir 50 mg once daily (group B), or an intensified four‐drug regimen (TAF 10 mg plus FTC 200 mg, dolutegravir 50 mg, darunavir 800 mg, and cobicistat 150 mg once daily) (group C). The primary endpoint was the decrease of HIV‐DNA copies/106 peripheral blood mononuclear cells (PBMCs) at weeks (W) 12 and 48. Secondary endpoints were increased in CD4+ cells and in CD4+/CD8+ ratio and percentage of PLWH reaching undetectable HIV‐RNA. HIV‐DNA was quantified by Droplet Digital PCR (Biorad QX100) and normalized to RPP30 reference gene. This study was registered in ClinicalTrials.gov (number NCT04225325). Among 78 participants enrolled, 30 were randomized to group 1, 28 to group 2, and 20 to group 3. At baseline, median CD4+ count was 658/µL (476–790), HIV‐RNA 5.37 (4.38, 6.12) log10 copies/mL, without statistical difference in their change among groups at weeks 12 and 48 (p = 0.432 and 0.234, respectively). The trial was prematurely discontinued for slow accrual and for COVID‐19 pandemic‐associated restrictions. In the per‐protocol analysis, PLWH (n = 72) with undetectable viral load was 54.3% at W12 and 86.4% at W48. Interestingly, the CD4/CD8 ratio progressively increased over time, up to normalization in almost half of the cohort by week 48, despite a deflection in group 3; no difference was observed by the Fiebig stage (I–III vs. IV–VI). HIV‐DNA decreased from 4.46 (4.08, 4.81) log10 copies/106 PBMCs to 4.22 (3.79, 4.49) at week 12, and 3.87 (3.46, 4.34) at week 48, without difference among groups. At multivariable analysis, HIV‐DNA delta at W48 was associated only with the increase of CD4+ count by 100 cells/mm3 but not with the Fiebig stage, the CD4+/CD8+ ratio, and treatment arm, despite a higher decrease in group 3. Six adverse events were recorded during our study, which did not cause any withdrawal from the study. We observed a decrease in HIV‐DNA from baseline to W48 in PLWH treated during PHI, associated with an increase in CD4+ count, unrelated to the treatment arm.


  • Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects

    by Stefano Rusconi, Francesco Saladini, Maria Concetta Bellocchi, Laura Galli, Roberta Gagliardini, Lidia Gazzola, Daniela Francisci, Francesca Vichi, Emanuele Focà, Maurizio Zazzi, et al.